These presentations follow data recently presented at the 2013 American Diabetes Association annual meeting on the company's research version of an NMR-based diabetes risk index to stratify a patient's risk of developing type 2 diabetes. The data showed that high-risk patients may receive the benefit of more timely and focused clinical interventions intended to slow or prevent the progression to diabetes. The test provides researchers and clinicians with the means to help distinguish those individuals with a higher versus lower likelihood of progressing to type 2 diabetes at any given level of fasting plasma glucose (FPG) or glycosylated hemoglobin (HbA1c).
"The studies presented at AACC support our vision for NMR diagnostics to become standard of care in the management of cardiovascular, metabolic and inflammatory diseases," said
Richard O. Brajer
, chief executive officer of LipoScience. "These data add to the growing body of evidence and clinical utility of NMR-based assays in terms of more accurate and precise risk management, which may ultimately yield improved patient outcomes."
For more information about the posters and LipoScience's NMR technology, please visit LipoScience, Inc. at booth 5535.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the
test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million
tests have been ordered. LipoScience's automated clinical analyzer, Vantera
, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's expectations for the future demand for its products and the factors that drive such demand. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2013
and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at
. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
SOURCE LipoScience, Inc.